PeerCurrent.com|Stay current with the people and research shaping what comes next.

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Researcher

Amany E. Awad

Menoufia University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 8, 2026 · JOURNAL ARTICLE

Beyond CA-125: circulating cell-free DNA as the next-generation biomarker in ovarian malignancy

BMC Cancer

A prospective case–control study of modest size (150 participants) with clear separation between groups and strong ROC performance for a candidate biomarker, but surrogate endpoints (AUC, survival association) rather than a clinical trial of intervention, requiring confirmation in independent cohorts.

PromisingGamalat A. Elgedawy Cancer Genomics and Diagnostics Marwa L. Helal

Reported

Mean cfDNA—malignant group11.84 ng/mL

Mean cfDNA—benign group3.90 ng/mL

Mean cfDNA—control group0.23 ng/mL

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support